Janux Therapeutics, Inc. (JANX)
NASDAQ: JANX · Real-Time Price · USD
24.89
-0.08 (-0.32%)
Aug 15, 2025, 10:01 AM - Market open

Janux Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019
Net Income
-105.64-68.99-58.29-63.06-32.67-6.78
Upgrade
Depreciation & Amortization
2.082.061.960.840.110.01
Upgrade
Loss (Gain) From Sale of Assets
----0-
Upgrade
Loss (Gain) From Sale of Investments
-15.25-10.59-7.69-2.18-0.17-
Upgrade
Stock-Based Compensation
43.333.0220.0117.26.910.07
Upgrade
Other Operating Activities
-----1.94
Upgrade
Change in Accounts Receivable
7.5---8-8
Upgrade
Change in Accounts Payable
2.211.580.28-0.292.140.01
Upgrade
Change in Unearned Revenue
-0.09-1.71-5.921.76-2.148
Upgrade
Change in Other Net Operating Assets
6.10.81-0.912.810.840.38
Upgrade
Operating Cash Flow
-59.79-43.81-50.58-42.92-16.98-4.37
Upgrade
Capital Expenditures
-0.91-0.36-1.85-6.45-1.48-
Upgrade
Investment in Securities
-291.32-257.66-39.3464.71-339.48-
Upgrade
Investing Cash Flow
-292.23-258.02-41.1958.27-340.96-
Upgrade
Short-Term Debt Issued
-----2.5
Upgrade
Total Debt Issued
-----2.5
Upgrade
Net Debt Issued (Repaid)
-----2.5
Upgrade
Issuance of Common Stock
390.15713.2459.550.5205.980.07
Upgrade
Other Financing Activities
-0.35----0.45-
Upgrade
Financing Cash Flow
389.81713.2459.550.5386.5211.52
Upgrade
Net Cash Flow
37.78411.4-32.2215.8428.597.16
Upgrade
Free Cash Flow
-60.7-44.17-52.43-49.37-18.46-4.37
Upgrade
Free Cash Flow Margin
-13827.79%-417.20%-648.58%-573.24%-507.51%-
Upgrade
Free Cash Flow Per Share
-1.03-0.82-1.19-1.19-0.78-4.77
Upgrade
Levered Free Cash Flow
-30.38-26.14-29.52-30.560.58-8.77
Upgrade
Unlevered Free Cash Flow
-30.38-26.14-29.52-30.560.58-8.64
Upgrade
Change in Working Capital
15.720.69-6.554.288.840.39
Upgrade
Updated May 8, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q